Using next-generation sequencing (NGS) to test patients with non-small cell lung cancer (NSCLC) for all known genetic mutations associated with the disease appeared to be faster and more cost-effective than testing for one gene at a time – not to mention the results could have treatment implications.
Immunotherapy revolutionized the way we treat cancer. And now, researchers are using drugs to help jumpstart the immune system alongside chemotherapy to keep treatment moving forward.
Lung cancer has gone from being a dismal diagnosis — it still is very serious — to one that is the poster child for targeted therapeutics, immunotherapy and molecular diagnostics. These advancements are just the beginning.
Unique challenges become permanent fixtures in the minds of young adults who receive a diagnosis of a life-changing disease, but can change through advocacy support.
During National Women’s Lung Health Week, a lung cancer survivor shares her story and success with targeted therapy.
The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Tecentriq (atezolizumab) to be used in combination with Avastin (bevacizumab), carboplatin and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC).
Second cancers are common among patients with lung cancer, so how can risk be lowered?
Immune and targeted therapies build hope for patients with advanced lung cancer.
The combination of immunotherapy and chemotherapy, and more, is changing the landscape of the disease.
The Food and Drug Administration (FDA) granted a priority review to a supplemental biologics license application (sBLA) for frontline Keytruda (pembrolizumab) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), according to Merck (MSD), the manufacturer of the PD-1 inhibitor.
The Food and Drug Administration (FDA) approved Tagrisso as a first-line treatment for patients with non–small cell lung cancer (NSCLC) whose tumors harbor EGFR mutations.
The Food and Drug Administration (FDA) granted priority review to a supplemental biologics license application for Opdivo (nivolumab) for the treatment of patients with small cell lung cancer with disease progression following two or more lines of therapy.
Most recently, the dynamic duo of Yervoy (ipilimumab) plus Opdivo (nivolumab) – both checkpoint inhibitors – extended average progression-free survival (PFS) rates more than three times than standard-of-care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB).
Some patients with incurable non-small cell lung cancer (NSCLC) should receive chemotherapy concurrent with palliative thoracic radiation therapy, according to an updated guideline released by the American Society for Radiation Oncology (ASTRO).
New targeted therapies and immunotherapy treatments have rapidly improved the outcomes of patients with cancer. But not everyone is so lucky to have access to these agents.
FDA approves first treatment approved for stage 3 unresectable non-small cell lung cancer to reduce the risk of the cancer progressing, when the cancer has not worsened after chemoradiation.
Roswell Park Cancer Center researchers shed light on disease incidence among women.
Lorlatinib was granted a priority review to a new drug application (NDA) for patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on one or more ALK tyrosine kinases inhibitors (TKIs).
Lung cancer is the leading cause of cancer-related death for women in the United States, but often does not get as much attention as other malignancies. In an effort to change that, and to one day decrease the number of women who are dying from the disease, the bipartisan Women and Lung Cancer Research and Preventative Services Act was reintroduced into Congress.
A new study showed that a large percentage of patients do not receive standard-of-care.
Not all patients with non-small cell lung cancer (NSCLC) respond to immunotherapy, so researchers are exploring the use of combination regimens, including immune checkpoint inhibitors and chemotherapy, to improve outcomes in these patients.
Throughout her life and especially in her fight against lung cancer, Mom set us an example in unconditional devotion, taught our family valuable life lessons and never lost her indomitable spirit.
The Food and Drug Administration (FDA) expanded the approved use for Gilotrif (afatinib). The drug can now be used to treat patients with metastatic non-small cell lung cancer (NSCLC) who have uncommon EGFR alterations in L861Q, G719X and/or S768I.
A four-drug combination, including Tecentriq (atezolizumab), Avastin (bevacizumab), carboplatin and paclitaxel, delayed progression or death by 38 percent in patients with advanced non-squamous non–small cell lung cancer (NSCLC), compared to those who were treated with Avastin alone.
Although ROS1 mutations are quite rare in patients with non-small cell lung cancer (NSCLC), testing for the mutation in all who have the disease is important, as it can play a vital role in determining a treatment plan.
